Drug interactions of Avatrombopag

1.Effect of Other Drugs on Avatrombopag in Patients with Chronic Immune Thrombocytopenia

Moderate or Strong Dual Inhibitors of CYP2C9 and CYP3A4

Concomitant use with a moderate or strong dual inhibitor of CYP2C9 and CYP3A4 increases avatrombopag AUC, which may increase the risk of Avatrombopag toxicities. Reduce the starting dosage of Avatrombopag when used concomitantly with a moderate or strong dual inhibitor of CYP2C9 and CYP3A4.

In patients starting moderate or strong dual inhibitors of CYP2C9 and CYP3A4 while receiving Avatrombopag, monitor platelet counts and adjust Avatrombopag dose as necessary.

Moderate or Strong Dual Inducers of CYP2C9 and CYP3A4

Concomitant use with a moderate or strong dual inducer of CYP2C9 and CYP3A4 decreases avatrombopag AUC, which may reduce Avatrombopag efficacy. Increase the recommended starting dosage of Avatrombopag when used concomitantly with a moderate or strong dual inducer of CYP2C9 and CYP3A4.

In patients starting moderate or strong dual inducers of CYP2C9 and CYP3A4 while receiving Avatrombopag, monitor platelet counts and adjust Avatrombopag dose as necessary.

Patients with Chronic Liver Disease

No dosage adjustments are required for patients with chronic liver disease. 

from FDA，2021.06